From our survey

We expected hostility to ketamine and found doubt instead

If you think ketamine therapy sounds like a bad idea, you are in a bigger room than you probably assume, and a different one.

Before building anything, we paid Pollfish to reach 443 Midwest adults and asked each for a gut reaction to using ketamine, or its cousin esketamine, against depression or PTSD. We expected a wall. What came back was doubt, which is different material.

Skeptical was the answer of 21 percent and negative of 9 percent. Cautious but open drew 34 percent. The hopeful or curious and the first-timers came to 18 percent apiece. Every figure is final.

Thirty-one percent doubt, nine percent refusal

Those two numbers get lumped together constantly, and they should not be. A skeptical answer is conditional: the claim has not been supported yet. A negative answer is a verdict, and only nine respondents in a hundred delivered one.

The doubt is mainstream; the refusal is not. And when we asked what would move them, respondents did not describe testimonials. They described institutions.

The doubters asked for paperwork, not a pitch

FDA approval was a deciding or major consideration for 59 percent of respondents, and insurance for 65 percent. When picking a provider, 85 percent put coverage in their top two.

This sample wants a regulator to have examined the treatment and a payer to have agreed to it, the same filters a cautious person would apply anyway.

Why the word "ketamine" hides three different things

Among our respondents, Spravato was an unknown to 73 percent, an empty name to 21 percent, and a known quantity to just 6 percent.

Spravato is esketamine in a nasal device. Its FDA approval is narrow: depression that earlier treatments failed to lift. It is given in a certified office where you are watched afterward and cannot drive yourself home, and there is a regulatory file behind it. Brain Recovery Centers, which offers it, describes the supervised Spravato process if you want to check those details against a real clinic.

IV ketamine at a clinic is the second arrangement. Ketamine is an old anesthetic with decades of hospital use, but using it for depression is off label: a physician prescribing outside the approved indication, which is legal and common, and which also means marketing claims around it are not reviewed like an approved label.

Compounded ketamine mailed home after a video visit is the third and loosest: no in-person monitoring, a compounded preparation rather than an approved manufactured product, and a business model that depends on you reordering.

The other number in this survey

We also asked about personal history. Almost three in four of our respondents, 72 percent, had watched standard medication fall short on depression, anxiety, or PTSD, whether their own or a loved one's: 37 percent directly, 22 percent through someone close, and 13 percent both ways.

That is the pressure behind the conversation. Nearly three quarters of a general sample have watched first-line treatment fail somebody. Skepticism about a new option and exhaustion with the old ones live in the same households.

Doubt is not the obstacle in this category. Silence is. Most people are not rejecting the approved treatment. They have not been told it exists.

Where a doubtful person should actually take this

The sample already knows. For a first stop, 56 percent picked their primary doctor and 23 percent went with a psychiatrist or counselor; 12 percent chose an online search; a friend was the pick of 1 percent, and 5 percent were at a loss. Their own doctor's advice was also the persuader for 74 percent, while ads reached 2 percent and podcast hosts 1.

For a skeptic, that ordering is a gift. The decision does not have to be made against a clinic's sales page. It can go to the person who already has your chart, your medication history, and no financial stake in the answer.

Running the same test in St. Charles County

This survey did not isolate St. Charles, and we will not pretend it did. It does give a doubter in St. Charles, O'Fallon, or Wentzville an order of operations. Start with the doctor who knows your history. Ask your plan, by name, what it requires before anything is scheduled. Then find out how far the nearest certified site is, because a supervised dose means a ride home each visit, and a site across the Missouri River turns an appointment into an afternoon. Our respondents put nearness in their top two at a 43 percent rate, and for someone still unconvinced, distance is a fair thing to weigh.

Four questions that survive skepticism

• Is this the FDA-approved esketamine product, clinic IV ketamine, or a compounded at-home prescription? Make them answer in those words.
• What does my plan cover, in writing, before I start? Half our sample would accept a slower, paperwork-heavy path to keep coverage; 23 percent would rather pay to go faster, and 26 percent were unsure.
• What happens if it does not work for me, and when would you stop?
• Who monitors me during and after, and what are their credentials?

The honest limits of this study

This was a general-population read of attitudes, not a patient study of outcomes. Nothing in it says any treatment works, and we have no clinical data of our own. The study has no breakdown by first reaction, so how the skeptical 21 percent answered other questions is unknown to us, and we will not guess. Whether any treatment suits a specific person is a medical question for a clinician with that person's history; treat anyone online, us included, as background, not direction.

One thing is not conditional. If your own depression has you thinking about not being alive, reach out today instead of waiting for certainty about treatment. Text or dial 988 from any U.S. phone and a Lifeline counselor answers, free, at any hour. People come back from this, and the first step is telling one person.

Methodology

As publisher, we commissioned Pollfish study 395586438 and paid for it; fieldwork ended June 23, 2026. Pollfish drew the 443 respondents from its consumer panel as a general audience, not screened for any diagnosis. They were 18 to 64 and came from Missouri, Illinois, and the eight states around them. Where more than one answer was allowed, totals pass 100. The results come after the panel provider's final data-quality checks, and this piece sticks to whole-sample percentages, with no subgroup figures stated or implied.